BASELAUNCH
BaseLaunch is a venture builder firm located in Basel, Switzerland, focused on launching and developing startups across various therapeutic sectors, including oncology, immunology, and cardiovascular health. The program spans 15 months and is divided into two phases, providing non-dilutive funding and access to a network of leading healthcare partners. Participants benefit from the expertise of seasoned advisors and state-of-the-art infrastructure, while being integrated into Basel's vibrant biotech ecosystem. BaseLaunch is supported by prominent industry leaders such as Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche, and Roivant Sciences, along with various public and private collaborators.
Engimmune Therapeutics is a biotechnology company focused on developing innovative T cell receptor (TCR) therapies for cancer treatment, particularly targeting solid tumors. The company utilizes advanced technologies, including genome editing, high-throughput screening, deep sequencing, and machine learning, to create highly potent and specific immunotherapies. By addressing critical challenges in efficacy and safety, Engimmune aims to provide effective solutions for patients facing serious diseases with significant unmet medical needs. Through its comprehensive platform, the company is dedicated to advancing the next generation of TCR-based therapies, contributing to the evolving landscape of cancer treatment.
Stromal Therapeutics is the first biotechnological spin-off from the Kantonsspital St.Gallen. Stromal Therapeutics Building on the group’s unique domain expertise, the company has deployed state-of-the-art single-cell sequencing of human tissues to molecularly unravel the interplay of stromal tissue cytokines with the immune system
PharmaBiome AG is a biotechnology company based in Zurich, Switzerland, focused on developing innovative treatments for gastrointestinal diseases. Founded in 2015, the company specializes in the isolation and characterization of novel intestinal microbes to create microbiome therapies aimed at conditions such as Clostridium difficile infections, cancer, and ulcerative colitis. PharmaBiome's technology platform enables efficient development and production of defined, function-based therapies, facilitating a swift transition from identifying therapeutic mechanisms to clinical-ready products. The company aims to establish microbiota therapy as the new standard for treating intestinal diseases, providing alternatives to traditional fecal transplants for patients suffering from intestinal infections.
Polyneuron Pharmaceuticals AG is focused on developing innovative therapeutics for the treatment of antibody-mediated autoimmune disorders. The company is working on several drug candidates, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron utilizes a platform technology called Antibody-Catch, which is based on biodegradable glycopolymers. This technology selectively targets and eliminates pathological autoantibodies while preserving the integrity of the rest of the immune system. Founded in 2014 and headquartered in Basel, Switzerland, Polyneuron aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.